ISCO (International Stem Cell) Moat Score: 2/10 (As of Jul. 07, 2026)


ISCO International Stem Cell Corp ISCO
24 GF Score
Price $0.18
GF Value $0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is International Stem Cell Moat Score?

International Stem Cell ISCO -10.50% 24 Moat Score is 2 as of Jul. 07, 2026. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, International Stem Cell ranks better than 58.28% on this metric.

International Stem Cell has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

International Stem Cell has No Moat: International Stem Cell Corp operates in a niche biotech sector with limited market presence and no significant intellectual property or regulatory advantages. The company faces high competition and lacks durable cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes International Stem Cell might have No Moat - Very weak/transient advantages.

International Stem Cell  (OTCPK:ISCO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

International Stem Cell Moat Score Related Terms

ISCO vs ZVSA, AXIM, HEPA: Moat Score Comparison

For the Biotechnology subindustry, International Stem Cell's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

International Stem Cell Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Moat Score distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Moat Score falls into.


ISCO
24GF Score
International Stem Cell Corp ISCO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
International Stem Cell (ISCO) has a Moat Score of 2 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, International Stem Cell ranks #582 out of 1395 companies in the Biotechnology industry, placing it in the top 41.7%.
Is International Stem Cell's Moat Score too high?
International Stem Cell's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. International Stem Cell's value of 2 is 0% at this industry median. Based on the distribution chart, International Stem Cell ranks #582 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Moat Score compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #582 out of 1395 companies for Moat Score. This puts International Stem Cell in the upper half of its industry. The industry median Moat Score is 2.00. International Stem Cell's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Moat Score is 2 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Moat Score: 2
  • GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
  • GF Score™: 24/100 with 6 warning signs
  • Industry Position: 0% at the Biotechnology median (#582 of 1395)

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score

Get the complete analysis for ISCO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.13
GF Value